Equities Analysts Set Expectations for Surmodics Q3 Earnings

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Zacks Research decreased their Q3 2025 earnings per share estimates for Surmodics in a report released on Tuesday, May 27th. Zacks Research analyst D. Dey now expects that the company will post earnings of ($0.21) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.54) EPS, Q1 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.07) EPS and Q2 2027 earnings at $0.11 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. The business had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million.

Other equities analysts also recently issued reports about the company. Wall Street Zen initiated coverage on Surmodics in a research report on Monday, February 3rd. They issued a "hold" rating on the stock. Needham & Company LLC restated a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a research report on Friday, March 7th.

Surmodics Stock Performance

Shares of SRDX traded down $0.07 during trading hours on Friday, hitting $29.40. The stock had a trading volume of 6,845 shares, compared to its average volume of 259,133. The stock has a fifty day moving average price of $28.69 and a 200 day moving average price of $33.44. Surmodics has a 12 month low of $26.00 and a 12 month high of $42.44. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The firm has a market capitalization of $420.39 million, a PE ratio of -29.11 and a beta of 1.32.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Gabelli Funds LLC grew its stake in shares of Surmodics by 16.3% during the first quarter. Gabelli Funds LLC now owns 395,509 shares of the company's stock valued at $12,075,000 after buying an additional 55,550 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Surmodics in the fourth quarter worth approximately $11,880,000. Hsbc Holdings PLC grew its stake in Surmodics by 4.8% in the first quarter. Hsbc Holdings PLC now owns 267,042 shares of the company's stock worth $8,252,000 after purchasing an additional 12,344 shares in the last quarter. Gardner Lewis Asset Management L P grew its stake in Surmodics by 23.5% in the fourth quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock worth $10,410,000 after purchasing an additional 49,944 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Surmodics by 71.6% in the first quarter. Millennium Management LLC now owns 206,487 shares of the company's stock worth $6,304,000 after purchasing an additional 86,143 shares in the last quarter. Institutional investors own 96.63% of the company's stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).